<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02304159</url>
  </required_header>
  <id_info>
    <org_study_id>AI444284</org_study_id>
    <nct_id>NCT02304159</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Efficacy of Daclatasvir/Sofosbuvir/Ribavirin for 16 Versus 24 Weeks for HCV Genotype 3 Cirrhotics</brief_title>
  <official_title>A Randomized Study to Evaluate the Safety and Efficacy of Adding Daclatasvir to the Combination of Sofosbuvir (SOF) and Ribavirin (RBV) for 16 Weeks Versus 24 Weeks in Cirrhotic Subjects With Chronic Hepatitis C Infection Genotype 3</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tarek I. Hassanein, M.D., FACP, FAG, AGAF</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Southern California Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, open label, single center safety and efficacy study. At least 40&#xD;
      cirrhotic subjects with HCV genotype 3 will receive standard of care treatment of sofosbuvir&#xD;
      and ribavirin (SOF/RBV) as well as 60 mg daily of Daclatasvir (investigational product).&#xD;
      Subjects will be randomized in a 1:1 to receive either:&#xD;
&#xD;
        -  Group A: 16 weeks of DCV/SOF/RBV&#xD;
&#xD;
        -  Group B: 24 weeks of DCV/SOF/RBV&#xD;
&#xD;
      Subjects will return to the study center at various time points throughout the 16 or 24 weeks&#xD;
      of treatment in addition to 12 weeks post taking last dose of study drug to monitor safety&#xD;
      and efficacy. These visits will be according to standard of care.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2015</start_date>
  <completion_date type="Actual">August 2017</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>From baseline (start of study drugs) to last day of taking study drugs; an average of 20 weeks.</time_frame>
    <description>This field states the number of participants who had an adverse event</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Abnormal Safety Laboratory Tests (ALT and/or Total Bilirubin) That Required Discontinuing Study Drugs</measure>
    <time_frame>From baseline (start of study drugs) to last day of taking study drugs; an average of 20 weeks.</time_frame>
    <description>This field states the number of participants who had an abnormal ALT that required discontinuing study drugs and/or abnormal Total Bilirubin that required discontinuing study drugs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Undetectable HCV Virus 12 Weeks After Stopping Study Drugs</measure>
    <time_frame>From baseline (start of study drugs) until 12 weeks after stopping study drugs</time_frame>
    <description>Sustained Virologic Response (SVR) defined as undetectable HCV RNA 12 weeks after stopping study drugs.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Hepatitis C</condition>
  <condition>Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Group A - 16 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination of sofosbuvir 400 mg daily, ribavirin 1000-1200 mg daily (weight based) and daclatasvir 60 mg daily for 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B - 24 weeks</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Combination of sofosbuvir 400 mg daily, ribavirin 1000-1200 mg daily (weight based) and daclatasvir 60 mg daily for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>daclatasvir</intervention_name>
    <arm_group_label>Group A - 16 weeks</arm_group_label>
    <arm_group_label>Group B - 24 weeks</arm_group_label>
    <other_name>DCV, BMS-790052, Daklinza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir, Sovaldi</intervention_name>
    <arm_group_label>Group A - 16 weeks</arm_group_label>
    <arm_group_label>Group B - 24 weeks</arm_group_label>
    <other_name>SOF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <arm_group_label>Group A - 16 weeks</arm_group_label>
    <arm_group_label>Group B - 24 weeks</arm_group_label>
    <other_name>RBV</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed, written, informed consent must be available from the subject before any&#xD;
             study-specific procedures are performed;&#xD;
&#xD;
          2. Male or female 18-75 years of age;&#xD;
&#xD;
          3. All of the following at least 6 months prior to screening visit:&#xD;
&#xD;
               -  Documented HCV infection based on history of a positive serum anti-HCV antibody&#xD;
                  test and/or detectable levels of HCV RNA &gt;= 10,000 IU/mL, and&#xD;
&#xD;
               -  Documented HCV genotype 3.&#xD;
&#xD;
          4. Subjects with evidence of cirrhosis defined by either a liver biopsy &lt;= 3 years from&#xD;
             screening demonstrating a Metavir Fibrosis Score of F4 (or equivalent); OR Fibroscan®&#xD;
             &lt;= 1 year from screening &gt; 12.5 kPa. If a subject is evaluated by more than one&#xD;
             testing method, then the liver biopsy results take precedence;&#xD;
&#xD;
          5. Women of childbearing potential (WOCBP) must:&#xD;
&#xD;
               -  have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or&#xD;
                  equivalent units of HCG) within 24 hours prior to the start of study drug.&#xD;
&#xD;
               -  WOCBP must agree to follow instructions for method(s) of contraception for 7&#xD;
                  months post-treatment completion.&#xD;
&#xD;
               -  Men who are sexually active with WOCBP must agree to follow instructions for&#xD;
                  method(s) of contraception for the following duration for 7 months post-treatment&#xD;
                  completion.&#xD;
&#xD;
               -  Investigators shall counsel WOCBP and male subjects who are sexually active with&#xD;
                  WOCBP on the importance of pregnancy prevention and the implications of an&#xD;
                  unexpected pregnancy Investigators shall advise WOCBP and male subjects who are&#xD;
                  sexually active with WOCBP on the use of highly effective methods of&#xD;
                  contraception. Highly effective methods of contraception have a failure rate of &lt;&#xD;
                  1% per year when used consistently and correctly.&#xD;
&#xD;
          6. At minimum the subject agrees to the use of two methods of contraception, with at&#xD;
             least one method being highly effective as listed below:&#xD;
&#xD;
        Highly Effective Methods of Contraception&#xD;
&#xD;
          -  Male condoms with spermicide&#xD;
&#xD;
          -  Hormonal methods of contraception including combined oral contraceptive pills, vaginal&#xD;
             ring, injectables, implants, and intrauterine devices (IUDs) such as Mirena® by male&#xD;
             subject's WOCBP partner. Female partners of male subjects participating in the study&#xD;
             may use hormone-based contraceptives as one of the acceptable methods of contraception&#xD;
             since they will not be receiving study drug. WOCBP cannot use hormonal contraception&#xD;
             as one of the two methods of contraception because there are no data on the&#xD;
             effectiveness of systemic hormonal contraceptives in women taking SOF. However, WOCBP&#xD;
             can continue to use hormonal contraceptives, if necessary, in addition to 2 other&#xD;
             non-hormonal methods of contraception&#xD;
&#xD;
          -  Nonhormonal IUDs, such as ParaGard®&#xD;
&#xD;
          -  Tubal Ligation&#xD;
&#xD;
          -  Vasectomy&#xD;
&#xD;
          -  Complete Abstinence - defined as complete avoidance of heterosexual intercourse and is&#xD;
             an acceptable form of contraception for all study drugs. Subjects who choose complete&#xD;
             abstinence are not required to use a second method of contraception, but female&#xD;
             subjects must continue to have pregnancy tests. Acceptable alternate methods of highly&#xD;
             effective contraception must be discussed in the event that the subject chooses to&#xD;
             forego complete abstinence.&#xD;
&#xD;
        Less Effective Methods of Contraception&#xD;
&#xD;
          -  Diaphragm with spermicide&#xD;
&#xD;
          -  Cervical cap with spermicide&#xD;
&#xD;
          -  Vaginal sponge&#xD;
&#xD;
          -  Male condom without spermicide&#xD;
&#xD;
          -  Progestin only pills&#xD;
&#xD;
          -  Female condom; A male and female condom must not be used together&#xD;
&#xD;
        Azoospermic males, women who are not of childbearing potential and WOCBP who abstain from&#xD;
        heterosexual activity on a continuous basis, are exempt from contraceptive requirements.&#xD;
        However, WOCBP who abstain from heterosexual activity on a continuous basis must still&#xD;
        undergo pregnancy testing.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects who lack capacity to consent for themselves;&#xD;
&#xD;
          2. HCV Genotypes other than GT-3 infection; mixed genotype infections are not permitted;&#xD;
&#xD;
          3. Liver histology consistent with any other co-existing cause of chronic liver disease&#xD;
             (apart from fatty liver and/or Chronic Hepatitis B Virus);&#xD;
&#xD;
          4. Body Mass Index &gt; 40 at the Screening visit;&#xD;
&#xD;
          5. Any of the following within one month of screening:&#xD;
&#xD;
               -  Uncontrolled diabetes;&#xD;
&#xD;
               -  Unstable or uncontrolled thyroid disease (subjects requiring medication to&#xD;
                  control their thyroid disease are eligible if all other inclusion/exclusion&#xD;
                  criteria are met).&#xD;
&#xD;
          6. Any of the following within 6 months of screening visit, any of the following:&#xD;
&#xD;
               -  Decompensated liver disease, esophageal variceal bleeding, or a hepatic mass&#xD;
                  lesion suspicious for hepatocellular carcinoma (HCC);&#xD;
&#xD;
               -  Subjects who have been treated for HCV infection;&#xD;
&#xD;
               -  History of unstable or deteriorating cardiovascular or cerebrovascular disease;&#xD;
&#xD;
               -  Alcohol and/or drug.&#xD;
&#xD;
          7. QTcF ≥ 500 ms at the baseline visit.&#xD;
&#xD;
          8. Any of the following laboratory abnormalities within 8 weeks of the baseline visit:&#xD;
&#xD;
               -  Hemoglobin &lt;8 g/dL;&#xD;
&#xD;
               -  Absolute neutrophil count &lt;0.50 x 103 cells/μL;&#xD;
&#xD;
               -  Platelet count &lt;25 x 103 cells/μL;&#xD;
&#xD;
               -  Total bilirubin &gt;=3 mg/dL or &gt;=34 mol/L (with the exception of subjects with&#xD;
                  Gilbert's syndrome);&#xD;
&#xD;
               -  Albumin &lt;2.5g/dL;&#xD;
&#xD;
               -  Creatinine Clearance (CrCl) &lt;=50 mL/min (as estimated by Cockcroft and Gault).&#xD;
&#xD;
               -  Serum ALT &gt;=10 × ULN;&#xD;
&#xD;
               -  Alpha-fetoprotein &gt;200ng/mL.&#xD;
&#xD;
          9. Prior exposure to NS5A inhibitors is prohibited but other classes and pegIFN/RBV are&#xD;
             acceptable for treatment-experienced subjects;&#xD;
&#xD;
         10. Use of any prohibited or restricted treatment at least is five half-lives or 14 days&#xD;
             (whichever is longer) of the first dose of study drug (refer to section 4.5);&#xD;
&#xD;
         11. History of cancer within 1 year of the screening visit with the exception of localized&#xD;
             basal or squamous cell carcinoma;&#xD;
&#xD;
         12. Any gastrointestinal disease or surgical procedure that may impact the absorption of&#xD;
             study drug. (Subjects who have had cholecystectomy are permitted to enter the study);&#xD;
&#xD;
         13. Known HIV infection;&#xD;
&#xD;
         14. Confirmed, uncontrolled hypertension (any screening systolic blood pressure ≥ 160 mmHg&#xD;
             or diastolic blood pressure ≥ 100 mmHg should be excluded);&#xD;
&#xD;
         15. Presence or history of non-HCV chronic liver disease, including autoimmune hepatitis,&#xD;
             alpha-1-antitrypsin deficiency, hemochromatosis, Wilson's disease, drug- or&#xD;
             toxin-induced liver disease, alcohol-related liver disease, primary biliary cirrhosis&#xD;
             and sclerosing cholangitis. Subjects with fatty liver and/or chronic hepatitis B virus&#xD;
             in addition to HCV may be considered in the study;&#xD;
&#xD;
         16. Uncontrolled seizures disorder;&#xD;
&#xD;
         17. History of hemoglobinopathies, (e.g., thalassemia, sickle cell anemia, spherocytosis)&#xD;
             or other cause of hemolytic anemia, including autoimmune causes;&#xD;
&#xD;
         18. Active disease at screening visit known to cause significant alteration in immunologic&#xD;
             function including hematologic malignancy, sarcoidosis or autoimmune disorder (e.g.,&#xD;
             rheumatoid arthritis, systemic lupus erythematosis, leukemia, lymphoma, autoimmune&#xD;
             thyroid disease, scleroderma, unstable psoriasis, and multiple sclerosis);&#xD;
&#xD;
         19. Pregnant or lactating women or women who plan to become pregnant during the study;&#xD;
&#xD;
         20. History of hypersensitivity to drugs with a similar biochemical structure to DCV or&#xD;
             SOF or RBV;&#xD;
&#xD;
         21. Any other criteria or known contraindication that would exclude the subject from&#xD;
             receiving SOF or RBV (per the local label) or DCV;&#xD;
&#xD;
         22. Inability to tolerate oral medication;&#xD;
&#xD;
         23. Subjects, who in the opinion of the Investigator, are not suitable candidates for&#xD;
             enrollment or who would not comply with the requirements of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Southern California Research Center</name>
      <address>
        <city>Coronado</city>
        <state>California</state>
        <zip>92118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>November 17, 2014</study_first_submitted>
  <study_first_submitted_qc>November 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2014</study_first_posted>
  <results_first_submitted>February 4, 2018</results_first_submitted>
  <results_first_submitted_qc>April 23, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 24, 2019</results_first_posted>
  <last_update_submitted>April 23, 2019</last_update_submitted>
  <last_update_submitted_qc>April 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Southern California Research Center</investigator_affiliation>
    <investigator_full_name>Tarek I. Hassanein, M.D., FACP, FAG, AGAF</investigator_full_name>
    <investigator_title>President</investigator_title>
  </responsible_party>
  <keyword>HCV</keyword>
  <keyword>Genotype 3</keyword>
  <keyword>Treatment naive</keyword>
  <keyword>Treatment experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Sofosbuvir</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 5, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/59/NCT02304159/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 23, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/59/NCT02304159/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group A - 16 Weeks</title>
          <description>Combination of sofosbuvir 400 mg daily, ribavirin 1000-1200 mg daily (weight based) and daclatasvir 60 mg daily for 16 weeks&#xD;
daclatasvir, Daklinza&#xD;
Sofosbuvir, Sovaldi&#xD;
Ribavirin</description>
        </group>
        <group group_id="P2">
          <title>Group B - 24 Weeks</title>
          <description>Combination of sofosbuvir 400 mg daily, ribavirin 1000-1200 mg daily (weight based) and daclatasvir 60 mg daily for 24 weeks&#xD;
daclatasvir, Daklinza&#xD;
Sofosbuvir, Sovaldi&#xD;
Ribavirin</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>A total of 39 participants started treatment with sofosbuvir, ribavirin and daclatasvir. 21 were randomized to Group A (16 weeks of treatment). 18 were randomized to Group B (24 weeks of treatment).</population>
      <group_list>
        <group group_id="B1">
          <title>Group A - 16 Weeks</title>
          <description>Combination of sofosbuvir 400 mg daily, ribavirin 1000-1200 mg daily (weight based) and daclatasvir 60 mg daily for 16 weeks&#xD;
daclatasvir, Daklinza&#xD;
Sofosbuvir, Sovaldi&#xD;
Ribavirin</description>
        </group>
        <group group_id="B2">
          <title>Group B - 24 Weeks</title>
          <description>Combination of sofosbuvir 400 mg daily, ribavirin 1000-1200 mg daily (weight based) and daclatasvir 60 mg daily for 24 weeks&#xD;
daclatasvir, Daklinza&#xD;
Sofosbuvir, Sovaldi&#xD;
Ribavirin</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
            <count group_id="B2" value="18"/>
            <count group_id="B3" value="39"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.62" spread="8.15"/>
                    <measurement group_id="B2" value="55.72" spread="6.32"/>
                    <measurement group_id="B3" value="55.13" spread="7.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pre-treatment HCV RNA (viral load)</title>
          <units>IU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3009718.11" spread="3750275.88"/>
                    <measurement group_id="B2" value="3165043.17" spread="4871398.73"/>
                    <measurement group_id="B3" value="3085281.65" spread="4271365.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>This field states the number of participants who had an adverse event</description>
        <time_frame>From baseline (start of study drugs) to last day of taking study drugs; an average of 20 weeks.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A - 16 Weeks</title>
            <description>Combination of sofosbuvir 400 mg daily, ribavirin 1000-1200 mg daily (weight based) and daclatasvir 60 mg daily for 16 weeks&#xD;
daclatasvir, Daklinza&#xD;
Sofosbuvir, Sovaldi&#xD;
Ribavirin</description>
          </group>
          <group group_id="O2">
            <title>Group B - 24 Weeks</title>
            <description>Combination of sofosbuvir 400 mg daily, ribavirin 1000-1200 mg daily (weight based) and daclatasvir 60 mg daily for 24 weeks&#xD;
daclatasvir, Daklinza&#xD;
Sofosbuvir, Sovaldi&#xD;
Ribavirin</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>This field states the number of participants who had an adverse event</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Abnormal Safety Laboratory Tests (ALT and/or Total Bilirubin) That Required Discontinuing Study Drugs</title>
        <description>This field states the number of participants who had an abnormal ALT that required discontinuing study drugs and/or abnormal Total Bilirubin that required discontinuing study drugs.</description>
        <time_frame>From baseline (start of study drugs) to last day of taking study drugs; an average of 20 weeks.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A - 16 Weeks</title>
            <description>Combination of sofosbuvir 400 mg daily, ribavirin 1000-1200 mg daily (weight based) and daclatasvir 60 mg daily for 16 weeks&#xD;
daclatasvir, Daklinza&#xD;
Sofosbuvir, Sovaldi&#xD;
Ribavirin</description>
          </group>
          <group group_id="O2">
            <title>Group B - 24 Weeks</title>
            <description>Combination of sofosbuvir 400 mg daily, ribavirin 1000-1200 mg daily (weight based) and daclatasvir 60 mg daily for 24 weeks&#xD;
daclatasvir, Daklinza&#xD;
Sofosbuvir, Sovaldi&#xD;
Ribavirin</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal Safety Laboratory Tests (ALT and/or Total Bilirubin) That Required Discontinuing Study Drugs</title>
          <description>This field states the number of participants who had an abnormal ALT that required discontinuing study drugs and/or abnormal Total Bilirubin that required discontinuing study drugs.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Undetectable HCV Virus 12 Weeks After Stopping Study Drugs</title>
        <description>Sustained Virologic Response (SVR) defined as undetectable HCV RNA 12 weeks after stopping study drugs.</description>
        <time_frame>From baseline (start of study drugs) until 12 weeks after stopping study drugs</time_frame>
        <population>The analysis covers only the subjects who reached the 12 weeks after stopping study drugs time point. 19 of 21 participants randomized to Group A reached that timepoint and 16 of 18 participants randomized to Group B reached that timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A - 16 Weeks</title>
            <description>Combination of sofosbuvir 400 mg daily, ribavirin 1000-1200 mg daily (weight based) and daclatasvir 60 mg daily for 16 weeks&#xD;
daclatasvir, Daklinza&#xD;
Sofosbuvir, Sovaldi&#xD;
Ribavirin</description>
          </group>
          <group group_id="O2">
            <title>Group B - 24 Weeks</title>
            <description>Combination of sofosbuvir 400 mg daily, ribavirin 1000-1200 mg daily (weight based) and daclatasvir 60 mg daily for 24 weeks&#xD;
daclatasvir, Daklinza&#xD;
Sofosbuvir, Sovaldi&#xD;
Ribavirin</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Undetectable HCV Virus 12 Weeks After Stopping Study Drugs</title>
          <description>Sustained Virologic Response (SVR) defined as undetectable HCV RNA 12 weeks after stopping study drugs.</description>
          <population>The analysis covers only the subjects who reached the 12 weeks after stopping study drugs time point. 19 of 21 participants randomized to Group A reached that timepoint and 16 of 18 participants randomized to Group B reached that timepoint.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From start of treatment to 12 weeks after stopping treatment.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group A - 16 Weeks of Treatment</title>
          <description>Combination of sofosbuvir 400 mg daily, ribavirin 1000-1200 mg daily (weight based) and daclatasvir 60 mg daily for 16 weeks&#xD;
daclatasvir, Daklinza&#xD;
Sofosbuvir, Sovaldi&#xD;
Ribavirin</description>
        </group>
        <group group_id="E2">
          <title>Group A - 24 Weeks of Treatment</title>
          <description>Combination of sofosbuvir 400 mg daily, ribavirin 1000-1200 mg daily (weight based) and daclatasvir 60 mg daily for 24 weeks&#xD;
daclatasvir, Daklinza&#xD;
Sofosbuvir, Sovaldi&#xD;
Ribavirin</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Violence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Flu-like symptoms</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="21"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Decompensation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mood Changes</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="21"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study received IND approval in November 2014. Daclatasvir received initial FDA approval in July 2015. Participants were randomized to receive daclatasvir for either 16 or 24 weeks and were followed per standard of care.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Tarek Hassanein</name_or_title>
      <organization>Southern California Research Center</organization>
      <phone>619-319-3993</phone>
      <email>thassanein@livercenters.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

